危机四伏,被“逼疯”的全球药王K药!

医深观
10 Apr

作为肿瘤免疫治疗时代的经典药物,默沙东的K药(帕博利珠单抗)自2014年FDA批准首个适应症以来,以年均超20%的销售增长缔造了医药史上的商业神话。2024年,K药以294.82亿美元的销售额,继续问鼎全球“药王”。 然而,在这传奇的背后正是暗流涌动的危机。01四面楚歌作为全球首个"泛癌种治疗"药物,K药通过激活患者自身免疫系统攻击肿瘤细胞。该款PD-1抑制剂已覆盖从黑色素瘤到肺癌、乳腺癌等20...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10